Anzalone Christopher Richard

Chief Executive Officer, DirectorARROWHEAD PHARMACEUTICALS, INC. (ARWR) · full profile →Form 4 · filed Dec 16, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$12.3M
Net Open-Market Flow
-$12.3M
Transactions
13
13 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 16, 2025Sell(S)7K$64.29$428K3.9M
Dec 16, 2025Sell(S)166$66.77$11K3.9M
Dec 16, 2025Sell(S)1K$65.77$86K3.9M
Dec 16, 2025Sell(S)1K$64.96$65K3.9M
Dec 16, 2025Sell(S)8K$62.94$533K3.9M
Dec 16, 2025Sell(S)14K$62.12$876K3.9M
Dec 16, 2025Sell(S)11K$61.25$671K4.0M
Dec 16, 2025Sell(S)8K$60.51$509K4.0M
Dec 16, 2025Sell(S)3K$67.87$219K3.9M
Dec 15, 2025Sell(S)21K$69.28$1.5M4.0M
Dec 15, 2025Sell(S)101K$68.67$6.9M4.0M
Dec 15, 2025Sell(S)8K$69.96$570K4.0M
Dec 12, 2025Grant(A)180K$04.1M

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001423029-25-000003) within minutes of acceptance. Every field above traces to the original document. Verify it directly: